Advances on the roles of tenascin-C in cancer.
Immunity
Metastasis
Tenascin-C
Tumor
Journal
Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457
Informations de publication
Date de publication:
15 09 2022
15 09 2022
Historique:
entrez:
14
9
2022
pubmed:
15
9
2022
medline:
17
9
2022
Statut:
ppublish
Résumé
The roles of the extracellular matrix molecule tenascin-C (TNC) in health and disease have been extensively reviewed since its discovery over 40 years ago. Here, we will describe recent insights into the roles of TNC in tumorigenesis, angiogenesis, immunity and metastasis. In addition to high levels of expression in tumors, and during chronic inflammation, and bacterial and viral infection, TNC is also expressed in lymphoid organs. This supports potential roles for TNC in immunity control. Advances using murine models with engineered TNC levels were instrumental in the discovery of important functions of TNC as a danger-associated molecular pattern (DAMP) molecule in tissue repair and revealed multiple TNC actions in tumor progression. TNC acts through distinct mechanisms on many different cell types with immune cells coming into focus as important targets of TNC in cancer. We will describe how this knowledge could be exploited for cancer disease management, in particular for immune (checkpoint) therapies.
Identifiants
pubmed: 36102918
pii: 276631
doi: 10.1242/jcs.260244
pmc: PMC9584351
pii:
doi:
Substances chimiques
Tenascin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Institut National de la Santé et de la Recherche Médicale
Organisme : Agence Nationale de la Recherche
Organisme : Ligue contre le cancer
Organisme : Academy of Finland
ID : 326291
Organisme : University of Oulu
Organisme : Finnish Cancer Institute
Organisme : Deutsche Forschungsgemeinschaft
ID : FOR2722-384170921
Organisme : Chinese Scholarship Council
Informations de copyright
© 2022. Published by The Company of Biologists Ltd.
Déclaration de conflit d'intérêts
Competing interests G.O. has filed patents on the discovery of TNC targeting peptides (WO2021233766A1) and nanobodies (EP21305210.3). All other authors declare no competing or financial interests.
Références
J Cell Commun Signal. 2009 Dec;3(3-4):287-310
pubmed: 19838819
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16002-7
pubmed: 21911392
Oncoimmunology. 2018 Aug 6;7(10):e1478647
pubmed: 30288344
J Biol Chem. 2014 Jun 20;289(25):17699-708
pubmed: 24808173
Mol Cells. 2012 Jul;34(1):35-41
pubmed: 22699754
Cancer Res. 2007 Jul 1;67(13):6163-73
pubmed: 17616673
Am J Pathol. 2010 Aug;177(2):1004-16
pubmed: 20616339
Science. 2010 May 7;328(5979):749-52
pubmed: 20339029
Am J Pathol. 2011 Feb;178(2):754-63
pubmed: 21281808
Front Immunol. 2020 Feb 18;11:223
pubmed: 32133005
Oncotarget. 2017 Jun 29;9(2):1760-1771
pubmed: 29416729
J Investig Dermatol Symp Proc. 2006 Sep;11(1):73-8
pubmed: 17069013
Nat Cancer. 2022 Apr;3(4):486-504
pubmed: 35469015
Kidney Int. 2019 Jan;95(1):62-74
pubmed: 30409456
Dev Cell. 2021 Dec 6;56(23):3203-3221.e11
pubmed: 34847378
Proteomics. 2019 Apr;19(8):e1800148
pubmed: 30582284
Kidney Int. 2020 May;97(5):1017-1031
pubmed: 32245660
J Biol Chem. 2007 Nov 30;282(48):34929-37
pubmed: 17901052
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Cancer Immunol Res. 2022 Apr 1;10(4):482-497
pubmed: 35362044
Front Immunol. 2021 Mar 15;12:635166
pubmed: 33790905
Sci Signal. 2016 Aug 30;9(443):ra86
pubmed: 27577261
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Int J Dev Biol. 2011;55(4-5):511-25
pubmed: 21769776
Front Immunol. 2020 Sep 30;11:577015
pubmed: 33101302
Cell Res. 2011 Oct;21(10):1470-86
pubmed: 21403679
J Cell Sci. 2002 Oct 15;115(Pt 20):3861-3
pubmed: 12244123
Front Immunol. 2020 May 07;11:784
pubmed: 32457745
Shock. 2020 Jul;54(1):62-69
pubmed: 31764620
Ann Rheum Dis. 2021 Jul;80(7):891-902
pubmed: 33858850
Oncogenesis. 2013 Aug 19;2:e65
pubmed: 23958855
Cancer Res. 2015 May 15;75(10):2095-108
pubmed: 25808872
Cancer Res. 2017 Nov 1;77(21):5977-5988
pubmed: 28916657
Int J Cancer. 2002 Mar 20;98(3):362-9
pubmed: 11920587
Nat Rev Immunol. 2020 Feb;20(2):75-76
pubmed: 31925406
Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5625-E5634
pubmed: 28652369
J Immunol. 2010 Aug 1;185(3):1450-9
pubmed: 20622113
FASEB J. 2011 Oct;25(10):3477-88
pubmed: 21705668
Front Immunol. 2021 Jul 05;12:636108
pubmed: 34290694
FEBS J. 2021 Sep;288(17):5190-5200
pubmed: 33098359
Arthritis Rheum. 2012 Jul;64(7):2179-90
pubmed: 22275298
Mol Cancer. 2019 Mar 11;18(1):39
pubmed: 30857545
Matrix Biol. 2014 Nov;40:46-53
pubmed: 25196097
J Histochem Cytochem. 2018 Apr;66(4):289-304
pubmed: 29385356
Cancer Res. 2018 Feb 15;78(4):950-961
pubmed: 29259017
Cancer Immunol Res. 2020 Mar;8(3):368-382
pubmed: 31941671
Sci Rep. 2017 Oct 6;7(1):12762
pubmed: 28986537
Ann Vasc Dis. 2018 Jun 25;11(2):169-180
pubmed: 30116408
Semin Cell Dev Biol. 2022 Aug;128:130-136
pubmed: 35400564
Nat Rev Cancer. 2015 Feb;15(2):73-79
pubmed: 25592648
Front Oncol. 2022 Jun 17;12:908247
pubmed: 35785162
JCI Insight. 2021 Mar 8;6(5):
pubmed: 33507879
J Cell Biol. 1994 Feb;124(4):619-26
pubmed: 8106557
Anticancer Res. 2014 Mar;34(3):1255-9
pubmed: 24596369
Cancer Res. 2001 Dec 1;61(23):8586-94
pubmed: 11731446
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Front Immunol. 2021 May 13;12:613438
pubmed: 34054795
Oncogene. 2020 Nov;39(46):6990-7004
pubmed: 33077835
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
EMBO Mol Med. 2021 Jun 7;13(6):e13270
pubmed: 33988305
Front Med (Lausanne). 2021 Nov 26;8:759273
pubmed: 34901073
Front Oncol. 2019 Apr 24;9:219
pubmed: 31069166
Cell Adh Migr. 2015;9(1-2):141-53
pubmed: 25569113
J Cell Sci. 2021 Nov 1;134(21):
pubmed: 34633031
J Cell Biol. 2020 Nov 2;219(11):
pubmed: 33053168
Oncotarget. 2014 Nov 15;5(21):10529-45
pubmed: 25301723
Cancer Res. 2019 May 15;79(10):2697-2708
pubmed: 30898840
Oncogene. 2022 Feb;41(6):757-769
pubmed: 34845375
EMBO Mol Med. 2018 Oct;10(10):
pubmed: 30190333
Theranostics. 2020 Feb 18;10(8):3622-3635
pubmed: 32206112
Cell Death Dis. 2019 Nov 21;10(12):879
pubmed: 31754182
Mol Cancer. 2014 Feb 05;13:22
pubmed: 24495796
Cell Adh Migr. 2015;9(1-2):48-82
pubmed: 25482829
J Cell Sci. 2016 Dec 1;129(23):4321-4327
pubmed: 27875272
Cancer. 2012 Aug 1;118(15):3670-80
pubmed: 22180017
Front Immunol. 2021 Mar 11;12:600979
pubmed: 33776992
Front Immunol. 2020 Dec 09;11:610096
pubmed: 33362799
Physiol Rev. 2014 Oct;94(4):1287-312
pubmed: 25287865
Mol Cell Biol. 1997 Jun;17(6):3202-9
pubmed: 9154819
J Am Soc Nephrol. 2017 Mar;28(3):785-801
pubmed: 27612995
Cancer Immunol Res. 2020 Sep;8(9):1122-1138
pubmed: 32665262
Br J Cancer. 2019 Nov;121(11):922-933
pubmed: 31649319
Br J Cancer. 2021 Nov;125(10):1399-1407
pubmed: 34564696
Cell Rep. 2013 Oct 31;5(2):482-92
pubmed: 24139798
Front Cell Dev Biol. 2021 Sep 20;9:733627
pubmed: 34616739
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Nat Med. 2011 Mar;17(3):320-9
pubmed: 21383745
Nat Cell Biol. 2016 Dec;18(12):1336-1345
pubmed: 27820599
Cell Rep. 2016 Dec 6;17(10):2607-2619
pubmed: 27926865
J Am Heart Assoc. 2014 Nov 05;3(6):e001052
pubmed: 25376187
Matrix Biol. 2019 Oct;83:26-47
pubmed: 31288084
Cold Spring Harb Perspect Biol. 2011 May 01;3(5):
pubmed: 21441591
Front Immunol. 2021 Apr 12;12:663902
pubmed: 33912190
PLoS One. 2013 Apr 18;8(4):e62076
pubmed: 23637968
Matrix Biol. 2020 Nov;93:95-114
pubmed: 32599145
Nat Commun. 2020 Jul 30;11(1):3806
pubmed: 32732922
Brain Behav Immun. 2019 Oct;81:470-483
pubmed: 31271872
Cell Adh Migr. 2015;9(1-2):4-13
pubmed: 25611571
Matrix Biol. 2022 Apr;108:20-38
pubmed: 35227929
J Cell Sci. 1999 Jun;112 ( Pt 12):1855-64
pubmed: 10341205
Front Immunol. 2022 Mar 16;13:824586
pubmed: 35371015
Sci Rep. 2018 Aug 28;8(1):12941
pubmed: 30154546
J Immunol. 2009 Jun 15;182(12):8015-25
pubmed: 19494327
Front Immunol. 2021 Mar 08;12:620541
pubmed: 33763067
Eur J Immunol. 1999 May;29(5):1435-47
pubmed: 10359097
Cell Mol Life Sci. 2011 Oct;68(19):3175-99
pubmed: 21818551
Microbiol Spectr. 2021 Sep 3;9(1):e0020721
pubmed: 34319124
Nat Rev Cancer. 2021 Apr;21(4):217-238
pubmed: 33589810
J Clin Invest. 2019 Jul 9;129(11):4609-4628
pubmed: 31287804
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Nat Commun. 2016 Nov 09;7:13322
pubmed: 27827359
Nat Med. 2011 Jun 26;17(7):867-74
pubmed: 21706029
Cell Adh Migr. 2015;9(1-2):112-24
pubmed: 25738825
Front Cell Dev Biol. 2021 May 24;9:673599
pubmed: 34109179
Cell Death Dis. 2021 Sep 29;12(10):890
pubmed: 34588421
Int J Mol Sci. 2021 May 29;22(11):
pubmed: 34072423
Cancer Lett. 2006 Dec 8;244(2):143-63
pubmed: 16632194